65,437 trials
Cerebral Palsy · CP · Spastic Cerebral Palsy
Primary: Change in Gross Motor Function Measure 66 (GMFM-66) Score — 7.5; 6.9 units on a scale — p=0.72
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 39.5; 65.9; 61.7 percentage of participants — p=0.001
Stress Urinary Incontinence
Primary: Subjective Cure of Urinary Incontinence at 12 Months After Surgery — 77; 72 Participants — p=0.43
Other Chronic Postoperative Pain
Primary: Severity of Acute Pain — 46; 31 mm — p=0.05
Bladder Cancer · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Primary: Objective Tumor Response — 15 Participants
Symptomatic Cervical Disc Disease
Primary: Individual Patient Overall Success — 127; 81; 67 participants
Visual Acuity
Primary: CLUE Handling — 55.73; 57.58; 64.39 Units on a scale
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
Dermatitis
Primary: Number of Participants With Change in Incontinence Associated Dermatitis Score — 13; 1; 2 participants
Mobility Limitation
Primary: Incidence of a Sitting-induced Pressure Ulcer — 19; 15; 75; 69 Participants — p=0.77
Cholecystitis · Stomach Cancer
Primary: Time to Intubation — 47.2; 31.0 sec
Visual Acuity
Primary: Contact Lens Wearing Time — 14.55; 14.63 Hours
Purpura, Thrombocytopenic, Idiopathic
Primary: Remission Duration — 3; 11 Participants
Recurrent Melanoma · Stage IIIB Skin Melanoma · Stage IIIC Skin Melanoma
Primary: Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and…
Diabetes
Primary: Dario Blood Glucose Monitoring System Accuracy at High Altitude (ISO 15197:2003) — 28.6; 71.4; 100; 32.5 percentage of participants